135 related articles for article (PubMed ID: 31984553)
1.
Satpati D; Vats K; Sharma R; Sarma HD; Dash A
J Pept Sci; 2020 Mar; 26(3):e3241. PubMed ID: 31984553
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of
Satpati D; Sharma R; Sarma HD; Dash A
Chem Biol Drug Des; 2018 Mar; 91(3):781-788. PubMed ID: 29130625
[TBL] [Abstract][Full Text] [Related]
3. Increase in negative charge of
Rinne SS; Dahlsson Leitao C; Gentry J; Mitran B; Abouzayed A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Sci Rep; 2019 Nov; 9(1):17710. PubMed ID: 31776413
[TBL] [Abstract][Full Text] [Related]
4. PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates.
Beaino W; Anderson CJ
J Nucl Med; 2014 Nov; 55(11):1856-63. PubMed ID: 25256059
[TBL] [Abstract][Full Text] [Related]
5.
Mittal S; Sharma R; Mallia MB; Sarma HD
Nucl Med Biol; 2021; 96-97():61-67. PubMed ID: 33838524
[TBL] [Abstract][Full Text] [Related]
6. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
[TBL] [Abstract][Full Text] [Related]
7.
Vats K; Sharma R; Sarma HD; Satpati D; Dash A
Anticancer Agents Med Chem; 2018; 18(9):1289-1294. PubMed ID: 29546835
[TBL] [Abstract][Full Text] [Related]
8. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
9. Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA.
Altai M; Strand J; Rosik D; Selvaraju RK; Eriksson Karlström A; Orlova A; Tolmachev V
Bioconjug Chem; 2013 Jun; 24(6):1102-9. PubMed ID: 23705574
[TBL] [Abstract][Full Text] [Related]
10. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
[TBL] [Abstract][Full Text] [Related]
11. Effect of Macro-Cyclic Bifunctional Chelators DOTA and NODAGA on Radiolabeling and
Vatsa R; Shukla J; Kumar S; Chakraboarty S; Dash A; Singh G; Mittal BR
Cancer Biother Radiopharm; 2019 Sep; 34(7):427-435. PubMed ID: 31112044
[No Abstract] [Full Text] [Related]
12. Comparative preclinical evaluation of
Trencsényi G; Dénes N; Nagy G; Kis A; Vida A; Farkas F; Szabó JP; Kovács T; Berényi E; Garai I; Bai P; Hunyadi J; Kertész I
J Pharm Biomed Anal; 2017 May; 139():54-64. PubMed ID: 28273651
[TBL] [Abstract][Full Text] [Related]
13. Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics.
Kumar P; Tripathi SK; Chen CP; Wickstrom E; Thakur ML
Mol Imaging Biol; 2019 Feb; 21(1):130-139. PubMed ID: 29802552
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeling and Preliminary Evaluation of Ga-68 Labeled NODAGA-Ubiquicidin Fragments for Prospective Infection Imaging.
Bhatt J; Mukherjee A; Korde A; Kumar M; Sarma HD; Dash A
Mol Imaging Biol; 2017 Feb; 19(1):59-67. PubMed ID: 27406090
[TBL] [Abstract][Full Text] [Related]
15. Facile preparation of a novel Ga-67-labeled NODAGA-conjugated lactam-cyclized alpha-MSH peptide at room temperature for melanoma targeting.
Xu J; Qiao Z; Gonzalez R; Miao Y
Bioorg Med Chem Lett; 2020 Dec; 30(24):127627. PubMed ID: 33141072
[TBL] [Abstract][Full Text] [Related]
16. (64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate.
Farkas R; Siwowska K; Ametamey SM; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2016 Jun; 13(6):1979-87. PubMed ID: 27145400
[TBL] [Abstract][Full Text] [Related]
17. ⁶⁸Ga-NODAGA-VEGF₁₂₁ for in vivo imaging of VEGF receptor expression.
Kang CM; Koo HJ; Choe YS; Choi JY; Lee KH; Kim BT
Nucl Med Biol; 2014 Jan; 41(1):51-7. PubMed ID: 24183611
[TBL] [Abstract][Full Text] [Related]
18. Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules.
Westerlund K; Honarvar H; Norrström E; Strand J; Mitran B; Orlova A; Eriksson Karlström A; Tolmachev V
Mol Pharm; 2016 May; 13(5):1668-78. PubMed ID: 27010700
[TBL] [Abstract][Full Text] [Related]
19. Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of
Dahlsson Leitao C; Rinne SS; Mitran B; Vorobyeva A; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30832342
[TBL] [Abstract][Full Text] [Related]
20. Toward realization of 'mix-and-use' approach in ⁶⁸Ga radiopharmacy: preparation, evaluation and preliminary clinical utilization of ⁶⁸Ga-labeled NODAGA-coupled RGD peptide derivative.
Chakraborty S; Chakravarty R; Vatsa R; Bhusari P; Sarma HD; Shukla J; Mittal BR; Dash A
Nucl Med Biol; 2016 Jan; 43(1):116-123. PubMed ID: 26527030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
